A multicenter, adaptive, randomized study of safety and efficacy in hospitalized adult patients with COVID-19.
The treatment of COVID-19 is still a major challenge for medical research, so new drugs are being explored or the use of existing drugs is being optimized. One of the new medicines is a cocktail of two monoclonal antibodies developed by AstraZeneca. The clinical evaluation of DisCoVeRy aims to evaluate the efficacy and safety of different therapeutics compared to the control group. A total of 1260 patients are planned to be included in the study. The sponsor of the multicenter clinical study is the French National Institute for Health and Medical Research, which conducts the study in three centers in the Czech Republic through RI CZECRIN.
Based on the decision of the Discovery Steering Committee, recruitment to the study was canceled on July 1, 2022, with a total of 237 enrolled patients. No patient in the Czech Republic was enrolled and thus the clinical trial was not started.
CZECRIN Office
Faculty of Medicine, Masaryk University Department of Pharmacology LRI CZECRIN Kamenice 5,625 00 Brno, Česká Republika
Info@czecrin.cz Phone: +420 549 498 165 Phone: +420 725 828 348
